From Our Perspective

FDA: From Our Perspective From Our Perspective

Site Structure

Anonymous (not verified) Thu, 11/02/2023 – 15:05

Navigational Page
On

Last Reviewed Date
Thu, 11/02/2023 – 00:00

Next Review Date
1 Year

Short Description
Insights from CDER leadership and experts on public health actions

Short Title
From Our Perspective

Detailed Description
Insights from CDER leadership and experts on public health actions

Body

FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development

By: Cassandra L. Taylor, public health advisor, Office of the Center Director, Center for Drug Evaluation and Research (CDER) and Schuyler Pruyn, project manager, Office of Executive Programs, CDER

FDA has a long history of reviewing clinical research for cannabis (such as marijuana and hemp) and cannabis-derived products (such as cannabidiol or CBD). Since the early 1970s, FDA has received more than 800 investigational new drug applications (INDs) for, and pre-investigational new drug applications (pre-INDs) related to cannabis and cannabis-derived products (CCDP). Over the last 10 years, there has been increased interest in studying CCDPs as medical treatment options. We have received double the number of IND and pre-IND applications during this time. We also have seen increased clinical research of new types of cannabis products and routes of administration (ROA), which is the way the drug is administered in the body.

More with Cassandra L. Taylor and Schuyler Pruyn

 

Previous From Our Perspectives

2023

2022

2021

2020

Source Organization

Bulk Approved
Off

Hide main image
hide

Display Short Description
Off

Regulated Product*

Sorting Order
10

Language

Place Paragraphs below the Datatable
Off

Add Subscription Box
Off

Display Short Title
On

#CBD #Hemp http://www.fda.gov/drugs/news-events-human-drugs/our-perspective November 2, 2023 7:05 pm